Provided by Tiger Fintech (Singapore) Pte. Ltd.

IceCure Medical Ltd.

1.42
+0.04002.90%
Post-market: 1.440.0200+1.41%19:47 EDT
Volume:172.13K
Turnover:242.30K
Market Cap:80.33M
PE:-4.96
High:1.45
Open:1.39
Low:1.38
Close:1.38
Loading ...

BRIEF-Icecure Medical Regains Full Nasdaq Compliance With Nasdaq Minimum Closing Bid Price Rule

Reuters
·
06 Jan

IceCure Medical Regains Nasdaq Compliance, Securing Market Position

TIPRANKS
·
06 Jan

IceCure Medical Regains Full Nasdaq Compliance with Nasdaq Minimum Closing Bid Price Rule

PR Newswire
·
06 Jan

Sector Update: Health Care Stocks Rise in Late Afternoon Trading

MT Newswires Live
·
04 Jan

IceCure Says European Patent Office Issues Intention to Grant Notice for Cryoablation System

MT Newswires Live
·
03 Jan

IceCure Medical Secures European Patent for Next-Generation Cryoablation Technology

TIPRANKS
·
03 Jan

IceCure Medical receives Intention to Grant notice from EPO

TIPRANKS
·
03 Jan

European Patent Office Issues Intention to Grant Notice to IceCure for its Next-Generation Cryoablation Technology

PR Newswire
·
03 Jan

Icecure Medical Appoints New Board Director with Financial Expertise

TIPRANKS
·
30 Dec 2024

Data on IceCure's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual Meeting

PR Newswire
·
16 Dec 2024

IceCure Medical’s Cryoablation Success in Kidney Tumors

TIPRANKS
·
05 Dec 2024

BRIEF-IceCure's ProSense® Cryoablation Safe and Effective in Destruction of Kidney Tumors with 88.7% Recurrence-Free Rate Based on Interim ICESECRET Study Results

Reuters
·
05 Dec 2024

IceCure Medical’s ProSense cryoablation shows efficacy in kidney tumor study

TIPRANKS
·
05 Dec 2024

Icecure's Prosense Cryoablation Safe, Effective in Kidney Tumors Destruction With 88.7% Recurrence-Free Rate Based on Interim Icesecret Study Results

THOMSON REUTERS
·
05 Dec 2024

Icecure Medical’s Strategic Position and Growth Potential Justifies Buy Rating

TIPRANKS
·
28 Nov 2024

Icecure Medical Price Target Maintained With a $2.50/Share by HC Wainwright & Co.

Dow Jones
·
28 Nov 2024